Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31390071 | 0.83 | HSD17B10 (0.67) | HSD17B10VCAM1KMT2ALMNAMEN1 | |
| SCHEMBL2954715 | 0.83 | HSD17B10 (0.67) | HSD17B10VCAM1KMT2ALMNAMEN1 | |
| SCHEMBL29360183 | 0.80 | HSD17B10 (1.00) | HSD17B10VCAM1KMT2ALMNAMEN1 | |
| SCHEMBL3030993 | 0.80 | LMNA (0.56) | HSD17B10KMT2ALMNAMEN1HTT | |
| SCHEMBL85918 | 0.80 | HSD17B10 (1.00) | HSD17B10VCAM1KMT2ALMNAMEN1 | |
| Dinitrochlorobenzene SCHEMBL29349476 | 0.77 | HSD17B10 (0.69) | HSD17B10VCAM1KMT2AALDH1A1TDP1 | |
| SCHEMBL790761 | 0.77 | TDP1 (0.61) | HSD17B10KMT2ALMNAMEN1HTT | |
| Dinitrochlorobenzene SCHEMBL20472381 | 0.77 | HSD17B10 (0.69) | HSD17B10VCAM1KMT2AALDH1A1TDP1 | |
| SCHEMBL4870825 | 0.77 | HSD17B10 (0.69) | HSD17B10VCAM1KMT2ALMNAMEN1 | |
| Dinitrochlorobenzene SCHEMBL39251 | 0.77 | HSD17B10 (0.69) | HSD17B10VCAM1KMT2AALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008152217-A2 | PROCESS FOR PREPARING 2-(N-BUTYL)-5-NITROBENZOFURAN | FINORGA (FR) | 2008-12-18 | — | — | WO | claimed |
| WO-2025054368-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2024125437-A1 | GSPT1 DEGRADATION AGENT AND USE THEREOF | 南京圣和药业股份有限公司 | 2024-06-20 | — | — | WO | disclosed |
| CN-118184639-A | GSPT1 degradation agent and application thereof | 南京圣和药业股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| CN-111909188-B | Compound, luminescent material and organic electroluminescent device | 烟台显华化工科技有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-111056994-B | Preparation method of vismodegib | 新发药业有限公司 | 2021-08-17 | — | — | CN | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| CN-111909188-A | Compound, luminescent material and organic electroluminescent device | 烟台显华化工科技有限公司 | 2020-11-10 | — | — | CN | disclosed |
| EP-1458723-A4 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E | 2005-12-08 | — | — | US | disclosed |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | SALVATI MARK E (US) | 2005-09-01 | — | — | US | disclosed |
| CN-1589271-A | Fused heterocyclic succinimide compounds and analogs thereof as modulators of nuclear hormone receptor function | BRISTOL MYERS SQUIBB CO (US) | 2005-03-02 | — | — | CN | disclosed |
| EP-1458723-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | Bristols-Myers Squibb Company (US) | 2004-09-22 | — | — | EP | disclosed |
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-6630504-B2 | Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction | PFIZER INC. | 2003-10-07 | — | — | US | disclosed |
| WO-2003062241-A1 | FUSED HETEROCYCLIC SUCCINIMIDECOMPOUNDS AND ANALOGS THEREOF, MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-31 | — | — | WO | disclosed |
| US-20020183303-A1 | Phenoxyphenylheterocyclyl derivatives as SSRIs | PFIZER INC. | 2002-12-05 | — | — | US | disclosed |
| EP-1184372-A1 | Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) | Pfizer Limited (GB) | 2002-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077605-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | HSD17B10 234/4885VCAM1 3646/4885KMT2A 1432/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | HSD17B10 4521/4885VCAM1 4799/4885KMT2A 1528/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | HSD17B10 4504/4885VCAM1 4796/4885KMT2A 1487/4885 |
| US-20050192253-A1 | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | HSD17B10 234/4885VCAM1 3646/4885KMT2A 1432/4885 |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | HSD17B10 4521/4885VCAM1 4799/4885KMT2A 1528/4885 |
| US-20050272799-A1 | Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function | NCOA1, NCOA3, NR5A2 | HSD17B10 234/4885VCAM1 3646/4885KMT2A 1432/4885 |
| US-20020183303-A1 | Phenoxyphenylheterocyclyl derivatives as SSRIs | CRHR1, NR3C1, HTR6 | HSD17B10 451/4885VCAM1 4070/4885KMT2A 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.